BenevolentAI Investor Conference Presentation Deck

TARGET VALIDATION Advanced in-house lab capabilities move programmes faster Cutting-edge technologies including invitro / in vico Biology, Chemistry, CMC, DMPK with in-house investment in CRISPR, RNA seq and human IPSC Work progresses rapidly from in-silico to in-vitro experimental test The more we do, the more we learn; experimental insights enrich our Knowledge Graph and enhance future target predictions Benevolent 14

View entire presentation